Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Core Insights - Chemomab Therapeutics is set to present clinical data on nebokitug (CM-101) for primary sclerosing cholangitis (PSC) at major scientific conferences in 2025, including DDW25, EASL 2025, and BSG LIVE'25 [1] Group 1: Conference Presentations - At DDW25, an oral presentation will highlight that CM-101, a monoclonal antibody targeting CCL24, was safe, well-tolerated, and showed improvements in biomarkers related to inflammation, fibrosis, and cholestasis in PSC patients [2] - EASL 2025 will feature two poster presentations: one assessing the pharmacokinetics and pharmacodynamics of CM-101 and its impact on disease biomarkers in PSC [3], and another discussing how CCL24 blockade alters the proteomic profile of PSC patients [4] - BSG LIVE'25 will include an oral presentation on the results from the SPRING Study regarding CM-101 in PSC patients [5] Group 2: Company Overview - Chemomab is a clinical-stage biotechnology company focused on developing therapeutics for fibro-inflammatory diseases with significant unmet needs [6] - Nebokitug (CM-101) is a first-in-class dual activity monoclonal antibody that neutralizes CCL24, demonstrating disease-modifying potential and a favorable safety profile in clinical studies [7] - Positive results from the Phase 2 SPRING trial in PSC have led the company to prepare for a potential Phase 3 trial, which aims for a streamlined pathway to regulatory approval [7]